Skip to content

Nsp1 from divergent coronaviruses has conserved endonuclease activity.

Sep 2026 · Journal of Molecular Biology · Vol 438, pp. 170014 · 0 citations · 59 references
Medicine

TL;DR

The results show that endonuclease activity is intrinsic to Nsp1 across divergent coronavirus genera, and this endonuclease activity is likely targeted towards host mRNAs via a diverse set of host mRNA binding cofactors.

Abstract

All alpha- and beta-coronaviruses encode nonstructural protein 1 (Nsp1), a major virulence factor that restricts host gene expression. Herein, using Nsp1 from divergent alpha- and beta-coronaviruses (SARS-CoV-2, MERS-CoV, and HCoV-229E), we reveal all tested coronavirus Nsp1 proteins have intrinsic endonuclease activity. Furthermore, this endonuclease function is abolished when a conserved arginine-lysine motif in the N-terminal domain (NTD) is disrupted. For SARS-CoV-2 Nsp1, the eukaryotic Initiation Factor 3g (eIF3g) and the 40S ribosome act as cofactors for enhancing the endonuclease function, but these host factors are not conserved for the endonuclease function of MERS-CoV and HCoV-229E Nsp1. We propose that SARS-CoV-2 Nsp1 uses eIF3g and the 40S ribosome to enhance its affinity for RNA and target host mRNAs. Similar enhancement in endonuclease activity is observed when Nsp1 from SARS-CoV-2, MERS-CoV, and HCoV-229E are cis-tethered to an RNA-binding module. Collectively, our results show that endonuclease activity is intrinsic to Nsp1 across divergent coronavirus genera, and this endonuclease activity is likely targeted towards host mRNAs via a diverse set of host mRNA binding cofactors.

View source

Similar papers

Open access Aug 2026

Mutations in SARS-CoV-2 Nsp1 are critical determinants of viral pathogenicity in mice

The reduced pathogenicity of rSARS-CoV-2 Nsp1 mutants highlights the potential for targeting Nsp1 for rational design of viral inhibitors and development of live-attenuated vaccine strategies as effective prophylactic and therapeutic treatments to combat SARS-CoV-2 and possibly other CoV infections.

Nathaniel Jackson, Fu-Chun Zhou, Anastasija Cupic et al. · 0 citations
Review Open access Sep 2026

Sars Cov-2 Variants – Meta – Analysis

COVID-19, a novel coronavirus first detected in Wuhan in December 2019, caused a global pandemic and prompted widespread public-health measures and vaccine development and stronger ACE2 binding that may help explain faster spread.

Shiva Kumar, Mohd Saquib, Pooran Bhati · 0 citations
Open access Sep 2026

A chimeric murine coronavirus with altered deISGylase and proteolytic activities exhibits attenuated viral pathogenesis

ABSTRACT All coronaviruses encode one or two multifunctional papain-like proteases (PLPs) with protease activity that cleaves the viral polyprotein, along with deubiquitinating (DUB) and deISGylase activities that remove ubiquitin and interferon-stimulated gene 15 (ISG15) from viral and host proteins. Studying the role...

Mudassir S. Ali, A. O'Brien, En-Ya Qing et al. · 0 citations
Review Open access Sep 2026

MERS-CoV accessory ORF proteins in innate immune evasion: an evidence-graded functional framework

This framework separates demonstrated mechanisms from inferred biological consequences and identifies the validation required before accessory-ORF biology can inform host-range assessment, therapeutic development, sequence surveillance, or rational attenuation of MERS-CoV infection.

Chun-Hua Wang, Xu-Hang Li, Yi Jiang et al. · 0 citations
Open access Sep 2026

Mutational screening reveals a cluster of residues within the SARS-CoV-2 nsp1 N-terminus that confers RNA-targeting selectivity

The SARS-CoV-2 nsp1 protein is a virulence factor that broadly inhibits cellular gene expression. Although cellular mRNAs are translationally inhibited by nsp1 and subsequently degraded, viral transcripts possess a 5′ leader sequence (CoV2L) that enables them to escape nsp1-mediated repression. Both transcript targetin...

Jaresley V. Guillen, Sherzod A. Tokamov, B. Glaunsinger · 0 citations
Open access Aug 2026

Nanobodies against the S2 region of the spike protein potently neutralize SARS-CoV-2 viruses and show resistance to viral immune escape

The results show the value of nanobody technology for identifying novel neutralising epitopes in the S2 region of beta-coronaviruses with potential for the development of new selective anti-viral agents.

John D. Clarke, Luke M. Jones, Imogen I. H. Buckle et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.